Table 2.
No. total patients |
No. diabetics | Odds Ratio** (95% CI) |
p | p – interaction: by race† |
p – interaction: by obesity†† |
|
---|---|---|---|---|---|---|
High Grade Disease | ||||||
Overall | 1262 | 233 | 1.73 (1.22 - 2.45) | 0.002 | 0.17 | |
White | 670 | 103 | 2.28 (1.33 - 3.91) | 0.003 | 0.47 | |
Non Obese | 488 | 58 | 2.08 (1.07 - 4.05) | 0.03 | ||
Obese | 182 | 45 | 2.52 (0.96 - 6.60) | 0.06 | ||
Black | 592 | 130 | 1.45 (0.90 - 2.33) | 0.13 | 0.88 | |
Non Obese | 406 | 72 | 1.48 (0.80 - 2.73) | 0.21 | ||
Obese | 186 | 58 | 1.56 (0.71 - 3.44) | 0.27 | ||
ECE | ||||||
Overall | 1262 | 233 | 1.25 (0.85 - 1.83) | 0.27 | 0.49 | |
White | 670 | 103 | 0.93 (0.53 - 1.63) | 0.81 | 0.94 | |
Non Obese | 488 | 58 | 1.04 (0.50 - 2.19) | 0.91 | ||
Obese | 182 | 45 | 0.68 (0.27 - 1.70) | 0.41 | ||
Black | 592 | 130 | 1.64 (0.94 - 2.85) | 0.08 | 0.41 | |
Non Obese | 406 | 72 | 2.00 (1.02 - 3.94) | 0.04 | ||
Obese | 186 | 58 | 1.25 (0.43 - 3.66) | 0.68 | ||
PSM | ||||||
Overall | 1262 | 233 | 1.11 (0.81 - 1.52) | 0.50 | 0.3 | |
White | 670 | 103 | 1.31 (0.82 - 2.10) | 0.25 | 0.07 | |
Non Obese | 488 | 58 | 0.92 (0.50 - 1.71) | 0.79 | ||
Obese | 182 | 45 | 2.07 (0.93 - 4.59) | 0.08 | ||
Black | 592 | 130 | 1.01 (0.65 - 1.55) | 0.98 | 0.32 | |
Non Obese | 406 | 72 | 0.86 (0.49 - 1.53) | 0.61 | ||
Obese | 186 | 58 | 1.28 (0.63 - 2.59) | 0.50 | ||
SVI | ||||||
Overall | 1262 | 233 | 1.73 (1.04 - 2.90) | 0.04 | 0.78 | |
White | 670 | 103 | 1.44 (0.64 - 3.25) | 0.38 | 0.35 | |
Non Obese | 488 | 58 | 1.16 (0.36 - 3.80) | 0.80 | ||
Obese | 182 | 45 | 1.31 (0.37 - 4.66) | 0.67 | ||
Black | 592 | 130 | 2.01 (1.02 - 3.99) | 0.05 | 0.18 | |
Non Obese | 406 | 72 | 2.78 (1.21 - 6.40) | 0.02 | ||
Obese | 186 | 58 | 0.93 (0.26 - 3.38) | 0.92 |
ECE – extracapsular extension, PSM – positive surgical margins SVI – seminal vesicle invasion
Obesity was defined as a BMI ≥ 30 kg/m2
Adjusted for age, year of surgery, race, BMI, clinical stage, biopsy Gleason score (except analysis of high-grade disease), center, and pre-operative PSA
p – interaction by race assessed by including the cross product term between diabetes and race in the model
p – interaction by obesity assessed by including the cross product term between obesity and race in the model